Malaria is a devastating disease caused by Plasmodium parasites, resulting in
approximately 435000 deaths in 2018. The impact of malaria is compounded by the …

Although many new anti-infectives have been discovered and developed solely using
phenotypic cellular screening and assay optimization, most researchers recognize that …

Malaria liver stages represent an ideal therapeutic target with a bottleneck in parasite load
and reduced clinical symptoms; however, current in vitro pre-erythrocytic (PE) models for …

The hydride transfer involved redox-neutral cascade cyclization has been developed to
construct the spirocyclic bisoxindoles featuring a [3, 4]-fused oxindole moiety from rationally …

Naturally derived chemical compounds are the foundation of much of our pharmacopeia,
especially in antiproliferative and anti-infective drug classes. Here, we report that a naturally …

Background Cipargamin (KAE609) is a novel spiroindolone class drug for the treatment of
malaria, currently undergoing phase 2 clinical development. This review provides an …

Although malaria remains a big burden to many countries that it threatens their socio-
economic stability, particularly in the countries where malaria is endemic, there have been …

Produced amidst the still rippling effects of a pandemic and as the world experiences the
increasing burden of global warming and a rapidly changing biosphere, the second edition …

The antimalarial activity of chemically diverse compounds, including the clinical candidate
cipargamin, has been linked to the ATPase PfATP4 in the malaria-causing parasite …

A promising new compound class for treating human malaria is the imidazolopiperazines
(IZP) class. IZP compounds KAF156 (Ganaplacide) and GNF179 are effective against …